West Pharmaceutical Services Stock Total Asset
| WST Stock | USD 239.26 9.95 3.99% |
West Pharmaceutical's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting West Stock price.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. West Pharmaceutical Services Company Total Asset Analysis
West Pharmaceutical's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current West Pharmaceutical Total Asset | 3.64 B |
Most of West Pharmaceutical's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, West Pharmaceutical Services is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, West Pharmaceutical Services has a Total Asset of 3.64 B. This is 51.55% lower than that of the Health Care Equipment & Supplies sector and 10.0% higher than that of the Health Care industry. The total asset for all United States stocks is 87.64% higher than that of the company.
West Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses West Pharmaceutical's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of West Pharmaceutical could also be used in its relative valuation, which is a method of valuing West Pharmaceutical by comparing valuation metrics of similar companies.West Pharmaceutical is currently under evaluation in total asset category among its peers.
West Fundamentals
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 17 B | ||||
| Shares Outstanding | 71.91 M | ||||
| Shares Owned By Insiders | 0.61 % | ||||
| Shares Owned By Institutions | 97.67 % | ||||
| Number Of Shares Shorted | 1.83 M | ||||
| Price To Earning | 40.71 X | ||||
| Price To Book | 5.87 X | ||||
| Price To Sales | 5.81 X | ||||
| Revenue | 2.89 B | ||||
| Gross Profit | 1.04 B | ||||
| EBITDA | 743.8 M | ||||
| Net Income | 492.7 M | ||||
| Cash And Equivalents | 484.6 M | ||||
| Cash Per Share | 9.85 X | ||||
| Total Debt | 305.3 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 3.80 X | ||||
| Book Value Per Share | 40.74 X | ||||
| Cash Flow From Operations | 653.4 M | ||||
| Short Ratio | 2.92 X | ||||
| Earnings Per Share | 6.68 X | ||||
| Price To Earnings To Growth | 3.46 X | ||||
| Target Price | 316.36 | ||||
| Number Of Employees | 10.6 K | ||||
| Beta | 1.09 | ||||
| Market Capitalization | 17.2 B | ||||
| Total Asset | 3.64 B | ||||
| Retained Earnings | 3.96 B | ||||
| Working Capital | 987.7 M | ||||
| Current Asset | 673.7 M | ||||
| Current Liabilities | 314.3 M | ||||
| Annual Yield | 0 % | ||||
| Five Year Return | 0.36 % | ||||
| Net Asset | 3.64 B | ||||
| Last Dividend Paid | 0.83 |
About West Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze West Pharmaceutical Services's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of West Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of West Pharmaceutical Services based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for West Stock Analysis
When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.